Avoiding Delays in Reporting Time-to-Event Randomized Trials: Calendar Backstops and Other Approaches
- 1 November 2024
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (31) , 3753-3760
Abstract
New oncology therapies that extend patients' lives beyond initial expectations and improving later-line treatments can lead to complications in clinical trial design and conduct. In particular, for trials with event-based analyses, the time to observe all the protocol-specified events can exceed the finite follow-up of a clinical trial or can lead to much delayed release of outcome data. With the advent of multiple classes of oncology therapies leading to much longer survival than in the past, this issue in clinical trial design and conduct has become increasingly important in recent years. We propose a straightforward prespecified backstop rule for trials with a time-to-event analysis and evaluate the impact of the rule with both simulated and real-world trial data. We then provide recommendations for implementing the rule across a range of oncology clinical trial settings.Keywords
This publication has 18 references indexed in Scilit:
- Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 studyThe Lancet Oncology, 2023
- Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk MelanomaCancer Discovery, 2022
- Information fraction estimation based on the number of events within the standard treatment regimenBiometrical Journal, 2020
- Noninferiority trials with nonadherence to the assigned randomized treatmentClinical Trials, 2019
- Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non–Muscle-Invasive Bladder Cancer on Tumor RecurrenceJAMA, 2018
- Data maturity and follow-up in time-to-event analysesInternational Journal of Epidemiology, 2018
- Information time scales for interim analyses of randomized clinical trialsClinical Trials, 2016
- Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint InhibitorsJNCI: Journal of the National Cancer Institute, 2015
- Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1JNCI: Journal of the National Cancer Institute, 2001
- Group sequential procedures: Calendar versus information timeStatistics in Medicine, 1989